Skip to main content
Clinical Trials/CTRI/2012/05/002697
CTRI/2012/05/002697CompletedPhase 3

Randomized study to evaluate the role of spironolactone and amiloride in the prevention of Rosiglitazone induced fluid retention in Type 2 Diabetes -

Diabetes Research Centre0 sites180 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
Phase 3
Status
Completed
Sponsor
Enrollment
180

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • Type II Diabetes mellitus
  • Drug Naive subjects
  • Female-post menopausal
  • subjects need to have HbA1C -7 to 15%
  • medications-SU or SU+mET or acarbose

Exclusion Criteria

  • Use of more than 3 oral anti-diabetic agents
  • Never on thiazolidinediones
  • SBP 170 mmHg and DBP 100 mg mm Hg
  • Type I Diabetes mellitus

Investigators

Sponsor
Diabetes Research Centre

Similar Trials